Verde Science Appoints International Banker Manfred A.
Schauer
LAS VEGAS, NV -- June 1st, 2015 -- (OTCPK:VRCI)Verde
Science Inc., a pharmaceutical research and development company
focused on developing a portfolio of cannabinoid based prescription
medicines to meet patients needs for a wide range of medical
conditions, is pleased to announce the appointment of Manfred
Schauer as head of the Asia Pacific Region.
Mr. Schauer is a seasoned international banker, entrepreneur and
investor with over four decades of business experience. He was
educated in Germany, followed by a 15 year career with Deutsche
Bank. Based in Hong Kong as Regional Treasurer he was responsible
for asset and liability and risk management, and all money market
and foreign exchange trading operations for Deutsche Banks Asia
Pacific subsidiary network in 13 countries. He built up similar
regional treasury capabilities for Amsterdam-Rotterdam Bank and
Continental Illinois National Bank based in Hong Kong and Japan for
another 5 years. From New Zealand Mr. Schauer now runs his own
independent consulting business. This involves a wide range of
international projects from corporate finance and early stage
funding, to mergers and acquisitions and general corporate and
management advisory services. Over the last dozen years he has been
involved in a number of companies in the USA and Canada.
Mr. Schauer commented, I am excited of being part of the new
Verde Science team. The company has an excellent opportunity to
grow quickly and attain a strong position in the burgeoning medical
marijuana pharma sector. I look forward to committing my expertise
and experience in order to play my part in building Verde Science
into a substantial and successful company.
Mr. Harp Sangha, Verdes CEO offered, Manfred Schauer is an
important addition to the Verde team. His international banking and
finance network and his vast experience and business acumen
compliments and strengthens our ability to successfully execute the
Verde business plan.
About Verde Science, Inc. (PINKSHEETS:VRCI)
Verde Science, Inc. (trading symbol PINKSHEETS:VRCI) is an early
stage pharmaceutical organization that has built a research team
focused on developing a portfolio of cannabinoid prescription
medicines to meet patient needs in a wide range of medical
conditions. Verde's scientists have identified a number of
promising areas in which to begin its immediate R&D program,
which will initially be based in India. The Verde Science team of
inter-disciplinary researchers includes scientists in Bioprocess
Engineering, Nanotechnology, Molecular Biology, Pharmaceutical
Sciences and Bio-Medical Devices that is focused on a streamlined
approach to the development of innovative treatment protocols aimed
at capturing considerable market share.
For further information please see our investor profile
available on our website:
Information
www.verdescienceinc.com
Louis Silver, Director of Investor Relations
Tel: 1-610-710-1303
lsilver@verdescienceinc.com
Safe Harbor Statements
Certain information contained in this news release constitutes
forward-looking statements as such term is used in applicable
United States and Canadian laws. Generally, these forward-looking
statements can be identified by the use of forward-looking
terminology such as expects or does not expect, is expected,
anticipates or does not anticipate, plans, estimates, intends or
believes, or that certain actions, events or results may, could,
would, might or will be taken, occur, or be
achieved. Forward-looking statements are based on the opinions
and estimates of management as of the date such statements are
made, and are subject to known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these factors are beyond the Companys ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements
contained in this news release can be found in the Companys filings
with the SEC. Such risks and other factors include, among others,
the ability to locate and acquire suitable interests in alternative
medicine manufacturing operations on terms acceptable to the
Company, the availability of financing on acceptable terms,
accidents, labor disputes, acts of God and other risks of the
alternative medicine industry including, without limitation, delays
in obtaining governmental approvals or permits, title disputes or
claims limitations on insurance coverage. The Company believes that
the expectations reflected in the forward-looking statements
included in this news release are reasonable; however, no assurance
can be given that these expectations will prove to be correct, and
such forward-looking statements should not be unduly relied upon.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.
SOURCE: Verde Science, Inc.
